

Status: Currently Official on 15-Feb-2025
 Official Date: Official as of 01-Aug-2017
 Document Type: USP Monographs
 DocId: GUID-29DE9D29-A005-48CF-8781-565E63FEDB61_1_en-US
 DOI: https://doi.org/10.31003/USPNF_M40427_01_01
 DOI Ref: 01wdg

© 2025 USPC
 Do not distribute

Indomethacin Oral Suspension

DEFINITION

Indomethacin Oral Suspension contains NLT 90.0% and NMT 110.0% of the labeled amount of indomethacin ($C_{19}H_{16}ClNO_4$).

IDENTIFICATION

- **A.** The UV absorption spectrum of the indomethacin peak of the *Sample solution* exhibits maxima and minima at the same wavelengths as those of the *Standard solution*, as obtained in the Assay.
- **B.** The retention time of the indomethacin peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

Solution A: 0.2% (v/v) [phosphoric acid](#) in [water](#)

Solution B: [Dehydrated alcohol](#) and [butyl alcohol](#) (80:50)

Mobile phase: *Solution B* and *Solution A* (39:61). Pass through a suitable filter of 0.5-μm or finer pore size.

Standard solution: 0.8 mg/mL of [USP Indomethacin RS](#) and 0.16 mg/mL of sorbic acid prepared as follows. Transfer appropriate amounts of [USP Indomethacin RS](#) and sorbic acid to a suitable volumetric flask. Add 20% of the total volume of *Solution A* and 30% of the total volume of *Solution B*, and sonicate for 5 min. Dilute with *Solution A* to the total volume.

Sample solution: Nominally 0.8 mg/mL of indomethacin prepared as follows. Transfer an appropriate volume of Oral Suspension, freshly mixed and free from air bubbles, to a suitable volumetric flask. Add 30% of *Solution B*, and sonicate for 10 min. Dilute with *Solution A* to volume, and pass through a suitable filter of 0.5-μm or finer pore size.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 240 nm. For *Identification A*, use a diode array detector in the range of 200–400 nm.

Column: 8-mm × 10-cm; packing L1

Flow rate: 3 mL/min

Injection volume: 15 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Resolution: NLT 4.0 between sorbic acid and indomethacin

Tailing factor: NMT 2.0 for indomethacin

Relative standard deviation: NMT 2.0% for indomethacin

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of indomethacin ($C_{19}H_{16}ClNO_4$) in the portion of Oral Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of indomethacin from the *Sample solution*

r_S = peak response of indomethacin from the *Standard solution*

C_S = concentration of [USP Indomethacin RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of indomethacin in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

OTHER COMPONENTS**PERFORMANCE TESTS**• **[DISSOLUTION \(711\)](#)**

Buffer solution: 0.01 M pH 7.2 phosphate buffer prepared by dissolving 1.36 g of [monobasic potassium phosphate](#) in 1 L of [water](#) and adjusting with 0.1 N [sodium hydroxide](#) to a pH of 7.2 ± 0.1

Medium: *Buffer solution*; 900 mL

Apparatus 2: 50 rpm

Time: 20 min

Standard solution: [USP Indomethacin RS](#) at a known concentration in *Medium*. [NOTE—A quantity of [methanol](#) not to exceed 1.0% of the volume of the *Standard solution* may be used to bring the USP Reference Standard into solution before dilution with *Medium*, and the solution may be sonicated to effect complete dissolution of the USP Reference Standard.]

Sample solution: Transfer to the surface of the *Medium* in the dissolution vessel a volume of Oral Suspension, freshly mixed and free from air bubbles, nominally equivalent to 25 mg of indomethacin. Filter portions of the solution under test, and suitably dilute with *Medium* if necessary.

Instrumental conditions

Mode: UV

Analytical wavelength: 320 nm

Analysis

Samples: *Standard solution* and *Sample solution*

Tolerances: NLT 80% (Q) of the labeled amount of indomethacin ($C_{19}H_{16}ClNO_4$) is dissolved.

• **[UNIFORMITY OF DOSAGE UNITS \(905\)](#)****For single-unit containers**

Acceptance criteria: Meets the requirements

• **[DELIVERABLE VOLUME \(698\)](#)****For multiple-unit containers**

Acceptance criteria: Meets the requirements

IMPURITIES• **CONTENT OF INDOMETHACIN RELATED COMPOUND B**

Solution A, Solution B, Mobile phase, Sample solution, and Chromatographic system: Proceed as directed in the Assay.

Standard stock solution: 0.09 mg/mL of [USP Indomethacin Related Compound B RS](#) in *Solution B*

Standard solution: 0.0018 mg/mL of [USP Indomethacin Related Compound B RS](#) prepared as follows. Transfer an adequate amount of *Standard stock solution* to a suitable volumetric flask containing 30% of the total volume of *Solution B*, and dilute with *Solution A* to the total volume.

System suitability

Sample: *Standard solution*

Suitability requirements

Capacity factor, k' : NLT 1.0

Relative standard deviation: NMT 2.5%

Analysis

Samples: *Sample solution* and *Standard solution*

Calculate the percentage of indomethacin related compound B in the portion of Oral Suspension taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of indomethacin related compound B from the *Sample solution*

r_S = peak response of indomethacin related compound B from the *Standard solution*

C_S = concentration of [USP Indomethacin Related Compound B RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of indomethacin in the *Sample solution* (mg/mL)

Acceptance criteria: NMT 0.44%

SPECIFIC TESTS• **[pH \(791\)](#):** 2.5–5.0